3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.
3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.
复制标题
DOI：
10.1016/j.virol.2016.01.004
复制
发表时间：
2016-03
期刊：
影响因子：
3.7
通讯作者：
Marasco WA
中科院分区：
文献类型：
--
作者：
Johnson RF;Bagci U;Keith L;Tang X;Mollura DJ;Zeitlin L;Qin J;Huzella L;Bartos CJ;Bohorova N;Bohorov O;Goodman C;Kim DH;Paulty MH;Velasco J;Whaley KJ;Johnson JC;Pettitt J;Ork BL;Solomon J;Oberlander N;Zhu Q;Sun J;Holbrook MR;Olinger GG;Baric RS;Hensley LE;Jahrling PB;Marasco WA
中东呼吸综合征冠状病毒(MERS-CoV)于2012年被确定为中东几个国家发生的一种严重、致命的呼吸道疾病的病原体。迄今为止，26个国家已有1600多例实验室确诊的MERS冠状病毒病例，病死率为36%。鉴于中东呼吸综合征流行地区，MERS冠状病毒有可能在每年的麦加朝圣期间传播，因此有必要制定对策。在这份报告中，我们描述了恒河猴感染5×106pfu MERS-CoV Jordan-n3/2012后的临床和放射学变化。用人抗MERS单抗3B11-N或抗HIV抗体E410-N处理两组NHP。MERS冠状病毒Jordan-n3/2012感染可通过计算机断层扫描导致可量化的变化，但限制了其他临床疾病体征。与感染、未治疗的受试者相比，3B11-N治疗的受试者出现明显的肺病理改变，表明该抗体可能是一种合适的MERS-CoV治疗方法。MERS-CoV Jordan-n3/2012挑战恒河猴导致一种轻微疾病。CT可以用来监测疾病进展，以帮助建立人类疾病的模型。用人类单抗3B11-N治疗可以减少疾病。
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×106 PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment. MERS-CoV Jordan-n3/2012 challenge of rhesus monkeys results in a mild disease. CT can be used to monitor disease progression to aid models of human disease. Treatment with the human monoclonal antibody 3B11-N resulted in decreased disease.